Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Never mind just found this in the handbook:
This is not applicable to non stock boards, as long as we are not engaging in the following:
USMJ - next week - time to loading WEEEEEEEEE
Golden Global Corp (GLDG) Finalizes Endorsement Deals for Combo Hitter
HOUSTON, TX -- (Marketwired) -- 12/08/15 -- Golden Global Corp. (OTC PINK: GLDG), along with its wholly owned subsidiary Combo Hitter, LLC., is excited to announce today the signing of two 5-year endorsement deals with UFC stars Stipe Miocic and Jessica "Evil" Eye. In addition, the company has also signed a 5-year endorsement deal with UFC Hall of Famer Mark "The Hammer" Coleman, the renowned UFC Heavyweight Champion who earned the nickname "Godfather of Ground & Pound." Both UFC fighters have committed to releasing individual training videos with their own custom-made Combo Hitter system in the near future. The UFC stars released the below statements following their endorsement:
"I tried the combo hitter and knew right away that this was something I wanted to get behind" - Stipe Miocic
"It's an amazing piece of equipment that is already helping me during my workouts; I look forward to being a part of the Combo Hitter team and spreading the word about this incredible piece of equipment." - Jessica "Evil" Eye
CEO, Robert Leyne Lee and Mike Starkweather, Chief Operating Officer commented, "We are excited to welcome Stipe, Jessica, and Mark to the Combo Hitter family. Their excellence and professionalism are a perfect fit for our brand and this is just one of many steps being taken to make Combo Hitter nationally recognized. We would also like to add that we are continuing to work hard and are making strides ina our business ventures, which includes the restoration of the company's fully reporting status with the SEC."
GLDG going to be huge imo! Product already exists and is gaining the support of talented UFC fighters! As of June 18, 2015, Stipe #3 in official UFC heavyweight rankings.
CRCO -thiiiiin to 0,0165 - only only 50000 share to 0,0165 - HOLY MOLYYYYYYYYYYY $$$$$$$$$$$$$$$$$$$$$$$$ C R C O $$$$$$$$$$$$$$$$$$$$$$$$
CRCO thinning out - run started equal - NOOOOOOOOOOOOOOOOW STRONG BUY ; 2016 NEWS $$$$$$$$$$$$$$$ C R C O $$$$$$$$$$$$$$$$$http://carolcopictures.com/
PFSD insiders buy $100k. $1,910,210 sales past 9 months. Wow!
CRCO thin to '005 - WAAAAAAAAAAAAAAAAAAATCH http://carolcopictures.com/
CRCO only 20000 in ASK than '005 LOOOK and mega great SS http://www.otcmarkets.com/stock/CRCO/profile
$PTRA chart setting up nicely for the Bulls next week
PFSD $100k insider buy. products sold at Walmart!
http://www.walmart.com/search/?query=ecoone%20pool%20conditioner&ty
Countdown to MERGE. Just days remaining before GDSI to finalized merge with RONTAN.
******* THE LARGEST MERGE IN THE HISTORY OF PENNIES . *******
********** MUST WATCH VIDEO >>>>THE COMPANY IS ABOUT TO MERGE ******
PFSD was just over .01...products sold at Wal Mart.
CDII looks now very good http://stockcharts.com/h-sc/ui?s=CDII
CDII very strong _ now green and better and better now NOOOOOOOOOOW BOOOOOOOOOOOOOOM
HUGE $FITX news out.
$FITX
EMBR big support yesterday and should test recent highs soon.
$PMCB PharmaCyte’s Novel Diabetes Treatment Approach Could Prove Superior to Other Methods Under Development
Forecasts for the number of people that will be diagnosed with diabetes in the coming years are staggering. While many treatments exist to treat some of the effects of diabetes on patients afflicted with the disease, a “holy grail” to truly treat the disease has yet to be developed. Clearly, an out of the box approach is required. If future test results affirm the data derived from recent studies, the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® diabetes treatment platform could emerge as the treatment of choice for this disease.
Dozens of studies and trials to treat Type 1 and Type 2 diabetes are ongoing, given that the size of the global diabetes market for therapeutic devices and drugs is expected to reach US $114.3 billion by 2018, according to a report by Transparency Market Research. However, since results have been mixed for even the largest and most successful companies, industry participants are now exploring new ideas and new approaches that have demonstrated efficacy in early studies, which could serve as an indirect or direct benefit to PharmaCyte.
For example, one of the top two players in diabetes treatment, Novo Nordisk (NYSE – NVO), announced that it is collaborating with IBM (NYSE – IBM) to combine IBM’s cognitive computing capabilities with diabetes research by collecting and analyzing real-time data from patients using Novo Nordisk treatments and devices. The hope is that this venture leads to improved solutions for diabetes management. Novo Nordisk also submitted a new type of fast-acting mealtime insulin to the FDA for approval, a departure from its primary offerings. Meanwhile, Novo Nordisk competitor Eli Lilly (NYSE – LLY), which has had six diabetes treatments approved since 2014 halted development of a promising diabetes treatment under development. If a company with 6 approved drugs in a treatment category is still working on the problem, and another leader is moving outside of its comfort zone in an effort to develop the most effective therapy available, it is an indication that the time is now for PharmaCyte.
The Company has the exclusive worldwide rights to use Melligen cells to treat diabetes. Melligen cells are genetically engineered from human liver cells and have been shown to secrete insulin in response to the concentrations of glucose (blood sugar) in their environment. A recent article published in scientific journal Molecular Therapy noted that when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal.
This observation illustrates that Melligen cells can reverse the diabetic condition. PharmaCyte plans to encapsulate a human cell line that has been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. Therefore, the Melligen cell line, when combined with Cell-in-a-Box® encapsulation, could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes and Type 2 insulin-dependent diabetes and could potentially replace them. As a result, we look for these shares to move toward the $0.20 level in early 2016.
For more information, refer to our previous sponsored PMCB Reports, Updates and Hot Topic Articles by visiting http://www.GoldmanResearch.com/
EMBR!! Website under construction--BOOM--300M MAXED O/S!!
Pest pilot website under development..
http://webcache.googleusercontent.com/search?q=cache:7e32Lw6GK5YJ:www.pestpilotinc.com/+&cd=8&hl=en&ct=clnk&gl=us
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=119258564
EMBR doubled my position here today!! Big run coming here
EMBR... the party starts tomorrow. Outstanding is maxed out and we made our pulled back after a 200% Run. The company announced an update within 15 to 30 days of December 5th.
NETE Nasdaq .225 HUGE$$$ NO RS! More huge news in a new filing. NETE got approved by the Nasdaq to remain listed on the Nasdaq until June 2016 where we have time now to get above $1.00 and remain there. I love it. Get ready. The next NETE HUGE run is so close after todays HUGE positive PR's once the word spreads.
http://ih.advfn.com/p.php?pid=nmona&article=69744077
"On December 17, 2015, Net Element, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The NASDAQ Stock Market notifying the Company that the initial period of 180 calendar days previously provided by the Staff to the Company to regain compliance with the NASDAQ Listing Rule 5550(a)(2) with respect to the minimum requirement for the closing bid price for the Company’s common stock for continued inclusion on The NASDAQ Capital Market (the “Rule”), was extended for an additional 180 calendar day period, or until June 13, 2016, to regain compliance with the Rule.
If the Company does not regain compliance with the Rule by June 13, 2016, the Staff will provide written notification to the Company that its common stock may be delisted. At that time, the Company may appeal the Staff’s delisting determination to a NASDAQ Hearings Panel (“Panel”). If the Company timely appeals, it would remain listed pending the Panel’s decision. There can be no assurance that, if the Company does appeal the delisting determination by the Staff to the Panel, that such appeal would be successful.
The Staff letter has no effect on the listing of the Company’s common stock at this time. The Staff advised the Company that, if at any time during this additional time period, the bid price for the Company’s common stock closes at $1.00 or more for a minimum of 10 consecutive business days as required under Listing Rule 5810(c)(3)(A), the Staff will provide written notification to the Company that it complies with the Rule.
The Company notified the Staff of its intention to regain compliance with the Rule during such additional compliance period, including by committing to effectuate a reverse stock split (which was approved by the Company’s stockholders at a special meeting of stockholders held by the Company in November of 2015) within such additional period to regain compliance (assuming the bid price requirement under the Rule is not otherwise satisfied within such period)."
MY MAN! Few Really Know How It's Done Around Here.... #EMPIRE
WE WILL RISE AGAIN. THEY CANNOT KEEP US DOWN FOR LONG.
LONG LIVE THE EMPIRE!!!
WE WILL 2016....
TAKING OFF TOMORROW. HAVE A GREAT WEEKEND EMPIRE. LET'S COME BACK STRONGER THAN EVER IN 2016. WON'T HOLD US DOWN!
$AXXE......REVERSAL STARTING
CRCO mega strong RUN - SS WEEEE http://www.otcmarkets.com/stock/CRCO/profile and http://carolcopictures.com/
CRCO loading loading loading loading - thin , a runner
Schrelli cooked the books
EMBR close @ .0015 would be mighty powerful.
YEAH,,,,BUT WHY IS KBIO HALTED AND RTRX IS NOT??? WHAT'S WRONG WITH THIS PICTURE
He did it all with a grand.
Followers
|
656
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
40899
|
Created
|
02/21/09
|
Type
|
Premium
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |